URGN 烏龍製藥
- 11.065
- +0.055+0.50%
烏龍製藥所有資訊
烏龍製藥 | SC 13D/A：超過5%持股股東披露文件(修正)-Pontifax Management III G.P. (2011) Ltd.(4.4%),Pontifax Management Fund III L.P.(4.4%)等
烏龍製藥 | SC 13G/A：超過5%持股股東披露文件(修正)-Point72 Asset Management, L.P.(3.6%),Point72 Capital Advisors, Inc.(3.6%)等
烏龍製藥 | SC 13G/A：超過5%持股股東披露文件(修正)-RA Capital Management, L.P.(7.1%),Peter Kolchinsky(7.1%)等
烏龍製藥 | SC 13G/A：超過5%持股股東披露文件(修正)-Great Point Partners, LLC(1.80%),Dr. Jeffrey R. Jay, M.D.(1.80%)等
烏龍製藥 | SC 13G/A：超過5%持股股東披露文件(修正)-Menora Mivtachim Holdings Ltd.(5.47%),Menora Mivtachim Pensions and Gemel Ltd.(4.79%)
烏龍製藥 | SC 13G/A：超過5%持股股東披露文件(修正)-RTW Investments, LP(9.99%),Roderick Wong, M.D.(9.99%)
烏龍製藥 | SC 13G/A：超過5%持股股東披露文件(修正)-Cowen Financial Products LLC(4.3%),Cowen and Company, LLC(0%)
烏龍製藥 | SC 13G：超過5%持股股東披露文件-Adage Capital Management, L.P.(8.87%),Robert Atchinson(8.87%)等
烏龍製藥 | SC 13G：超過5%持股股東披露文件-BlackRock, Inc.(5.9%)
烏龍製藥 | SC 13G：超過5%持股股東披露文件-Morgan Stanley(5.2%)
烏龍製藥 | 10-Q：2024財年三季報
烏龍製藥 | 8-K：UroGen Pharma 公佈 2024 年第三季度財務業績和業務亮點，包括可能在 2025 年推出 UGN-102
烏龍製藥 | SC 13G：超過5%持股股東披露文件-BlackRock, Inc.(5.9%)
烏龍製藥 | 4：持股變動聲明-高管 Degnan Chris
烏龍製藥 | 3：首次持股聲明-高管 Degnan Chris
烏龍製藥 | 8-K：重大事件
烏龍製藥 | 8-K：重大事件
烏龍製藥 | 8-K：重大事件
烏龍製藥 | 4：持股變動聲明-高管 Schoenberg Mark
烏龍製藥 | 4：持股變動聲明-高管 Smith Jason Drew
暫無數據